The car t-cell therapy condition center is a comprehensive resource for clinical news and expert insights on car t-cell therapy. Read more at OncLive.
June 18th 2025
SENTI-202 receives FDA orphan drug designation for treating relapsed/refractory hematologic malignancies, including AML.
Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.
June 17th 2025
Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.
June 16th 2025
Liso-cel generated deep and durable responses in relapsed/refractory marginal zone lymphoma.
Amrita Krishnan, MD, discusses key data may shape the evolving treatment landscape of multiple myeloma from ASCO 2025.
June 14th 2025
Anitocabtagene autoleucel yielded an overall response rate of 97% in relapsed/refractory multiple myeloma.
June 3rd 2025
The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.
June 2nd 2025
The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.
May 29th 2025
Kiavasch Mohammad Nejad Farid, MD, discussed the clinical utility of tabelecleucel in relapsed/refractory post-transplant lymphoproliferative disorder.
May 25th 2025
The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.
May 22nd 2025
There remains a significant unmet need for better treatments that prolong life and preserve the quality of life in women with metastatic breast cancer.
May 12th 2025
The allogeneic CAR T-cell therapy CT0596 was safe with clinical activity in relapsed/refractory multiple myeloma.
April 27th 2025
The top 5 OncLive videos of the week cover insights in chronic lymphocytic leukemia, ovarian cancer, multiple myeloma, and large B-cell lymphoma.
April 24th 2025
A multicenter review comparing ide-cel and cilta-cel in relapsed/refractory multiple myeloma showed better survival with cilta-cel but increased toxicity.
April 23rd 2025
Sairah Ahmed, MD, discusses safety data with NKTR-255 in patients with relapsed/refractory large B-cell lymphoma.
Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
April 21st 2025
Alfred L. Garfall, MD, MS, discusses the rationale of the phase 2 BMT CTN 1902 trial in multiple myeloma.
Andrew Ip, MD, discusses the need for real-world studies investigating the efficacy and safety of CAR T-cell therapy in patients with LBCL.
Michael R. Bishop, MD, explains the rationale for assessing the CAR T-cell therapy anito-cel in relapsed/refractory multiple myeloma.
Yeong “Christopher” Choi, PhD, MBA, discusses importance of product and process education to mitigate variability in CAR T-cell therapy manufacturing in hematologic malignancies.